BACKGROUND/AIMS: There is an increasing interest in using the Montreal Cognitive Assessment (MoCA) test as a monitoring tool in Alzheimer's disease (AD) in both research and clinical settings. Our aim was to investigate the utility of alternate forms of the MoCA in detecting cognitive deterioration in a sample of early AD patients followed longitudinally in an outpatient memory clinic. METHOD: Twenty-five patients with early-stage AD (prodromal or mild dementia) were administered the original version and one of two previously validated alternate forms of the MoCA within an interval of about 1 year. The decline over time and the rate of change of the MoCA were compared to the total score of a standardized neuropsychological assessment battery (Consortium to Establish a Registry of Alzheimer's Disease; CERAD-Plus). Responsiveness to change was determined by calculating standard response means and the respective effect sizes. RESULTS: Sixty percent of the sample showed a clinical decline on the clinical dementia rating (CDR) scale. There was significant deterioration in the MoCA and CERAD total scores. CONCLUSION: The results demonstrate that the MoCA is capable of detecting change over time and seems to be a valid tool with small to moderate sensitivity for monitoring cognitive change in early AD.
BACKGROUND/AIMS: There is an increasing interest in using the Montreal Cognitive Assessment (MoCA) test as a monitoring tool in Alzheimer's disease (AD) in both research and clinical settings. Our aim was to investigate the utility of alternate forms of the MoCA in detecting cognitive deterioration in a sample of early ADpatients followed longitudinally in an outpatient memory clinic. METHOD: Twenty-five patients with early-stage AD (prodromal or mild dementia) were administered the original version and one of two previously validated alternate forms of the MoCA within an interval of about 1 year. The decline over time and the rate of change of the MoCA were compared to the total score of a standardized neuropsychological assessment battery (Consortium to Establish a Registry of Alzheimer's Disease; CERAD-Plus). Responsiveness to change was determined by calculating standard response means and the respective effect sizes. RESULTS: Sixty percent of the sample showed a clinical decline on the clinical dementia rating (CDR) scale. There was significant deterioration in the MoCA and CERAD total scores. CONCLUSION: The results demonstrate that the MoCA is capable of detecting change over time and seems to be a valid tool with small to moderate sensitivity for monitoring cognitive change in early AD.
Authors: Marta Kaminska; Victoria P Mery; Anne-Louise Lafontaine; Ann Robinson; Andrea Benedetti; Priti Gros; R John Kimoff Journal: J Clin Sleep Med Date: 2018-05-15 Impact factor: 4.062
Authors: Michael Malek-Ahmadi; Kathy O'Connor; Sharon Schofield; David W Coon; Edward Zamrini Journal: Aging Clin Exp Res Date: 2017-11-29 Impact factor: 3.636
Authors: Annes J Claes; Suzanne de Backer; Paul Van de Heyning; Annick Gilles; Vincent Van Rompaey; Griet Mertens Journal: Eur Arch Otorhinolaryngol Date: 2018-04-18 Impact factor: 2.503
Authors: Achinoam Faust-Socher; Sarah Duff-Canning; Arthur Grabovsky; Melissa J Armstrong; Brandon Rothberg; Paul J Eslinger; Christopher A Meaney; Ruth B Schneider; David F Tang-Wai; Susan H Fox; Cindy Zadikoff; Nancy Kennedy; Kelvin L Chou; Carol Persad; Irene Litvan; Benjamin T Mast; Adam T Gerstenecker; Sandra Weintraub; William Reginold; Connie Marras Journal: Dement Geriatr Cogn Disord Date: 2019-07-17 Impact factor: 2.959